AMN
AMN Healthcare Services, Inc.
AMN's fundamentals are strong, but it looks expensive: trading at 14x earnings, below its usual 16x. Analysts expect earnings to fall sharply.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AMN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
AMN's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AMN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $29.74 | -21% |
| Current | 14x | $37.42 | — |
| Fair | 16x | $42.98 | +15% |
| Expensive | 32x | $88.16 | +136% |
| Forward | 40x | $37.42 | — |
Historical ranges are pointers, not guarantees.
AMN's PE is in its fair range at 14x. Analysts expect earnings to fall, which would put today's price at 40x next year's earnings, in its expensive range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AMN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Decline | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect AMN's earnings and revenue to decline, with profitability weakening.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over AMN on the outlook, with more favorable revenue and profitability expectations.
AMN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.93 | -66% |
| Q3 2026 | $2.76 | +$9.95 |
| Q2 2026 | $2.69 | +$10.46 |
| Q1 2026 | -$0.86 | +$3.47 |
| Q4 2025 | -$2.48 | +$1.37 |
| Q3 2025 | -$7.19 | -596% |
| Q2 2025 | -$7.77 | -392% |
| Q1 2025 | -$4.33 | -214% |
| Q4 2024 | -$3.85 | -172% |
AMN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AMN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $717.3M | +13% |
| Q2 2026 | $673.2M | +2.3% |
| Q1 2026 | $1.4B | +100% |
| Q4 2025 | $748.2M | +1.8% |
| Q3 2025 | $634.5M | -7.7% |
| Q2 2025 | $658.2M | -11% |
| Q1 2025 | $689.5M | -16% |
| Q4 2024 | $734.7M | -10% |
AMN's revenue is recovering but still below its 2022 peak: $717M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -0.5 points |
| Q2 2026 | 4% | +23 points |
| Q1 2026 | 8.5% | +6.7 points |
| Q4 2025 | 1.1% | +29 points |
| Q3 2025 | 7.5% | +4.3 points |
| Q2 2025 | -19% | -24 points |
| Q1 2025 | 1.8% | -3.1 points |
| Q4 2024 | -28% | -32 points |
AMN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AMN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AMN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$97.3M | -760% |
| Q2 2026 | -$198.5M | -389% |
| Q1 2026 | $555.2M | +571% |
| Q4 2025 | $67.6M | +19% |
| Q3 2025 | $14.8M | -69% |
| Q2 2025 | $68.7M | -4.8% |
| Q1 2025 | $82.7M | +31% |
| Q4 2024 | $56.6M | +$127.6M |
AMN usually generates cash, though not every quarter: the latest was −$97M, but it generated $327M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AMN on cash flow, with more consistent year-over-year improvement.
AMN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +433K shares |
| 1 year | +3.8% | +1.5M shares |
| 3 years | +4.8% | +1.8M shares |
| 5 years | -16% | -7.9M shares |
| Available history | -16% | -7.4M shares |
AMN has 40M diluted shares, up 3.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $8.4M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $250M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AMN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AMN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 7.6x | High |
| Q1 2025 | 26.5x | High |
| Q4 2024 | 15.5x | High |
| Q3 2024 | 3.6x | Elevated |
| Q2 2024 | 3.1x | Elevated |
AMN's net debt is about 1.4 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AMN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 50.2 | Neutral |
AMN's weekly RSI is 55 (neutral) and its Stochastic is 50 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AMN PE vs Healthcare Sector
| Metric | AMN | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 48% below |
| PE % | 40 | 29 | 11 pts above |
AMN is trading at 14x earnings, a 48% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AMN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.6 | 5.6% below |
| 20 week MA | $36.3 | 3% above |
| 50 week MA | $27.5 | 36% above |
| 100 week MA | $24.5 | 53% above |
| 200 week MA | $47.4 | 21% below |
AMN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AMN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.7 | $69.3 | +12% |
| 2021 | $69.3 | $122.3 | +77% |
| 2022 | $122.3 | $103.5 | -15% |
| 2023 | $103.5 | $74.9 | -28% |
| 2024 | $74.9 | $24.2 | -68% |
| 2025 | $24.2 | $16.1 | -34% |
| 2026 YTD | $16.1 | $37.4 | +132% |
AMN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.